Endocrine and Metabolic Disease Clinical Development Expertise
Overcoming complexities to bring more metabolic disease treatments to market successfully.
Metabolic and endocrine diseases are a rising therapy area focus for clinical research due to the high demand for novel therapies that are challenged with proving safety and efficacy. The development process is complicated and full of unknowns, and even the best metabolic therapeutic might not make it to the patients that need it, not because it does not work but because the design, data collection, and analysis were not done right.
At Veristat, we have assembled an extraordinary team of scientific-minded experts who have mastered the complexities of running metabolic disease trials. Our team has supported 300+ projects for endocrine/metabolic disorder treatments and the preparation of 30+ marketing applications - 60% of which have been approved or authorized so far!
Endocrine & Metabolic Projects
in Rare/Ultra-Rare Indications
in Biologic Therapeutics
Specialized Expertise from Consultation to Beyond Submission
Our solutions span the entire clinical development life-cycle - and are offered as a comprehensive, all-inclusive solution or as functional support. We provide strategic guidance for informed decision-making, operational support to mitigate trial risks, the statistical knowledge to prove safety and efficacy, the medical oversight to ensure patient safety, and the regulatory expertise to achieve approval success.
I would like to thank the entire team at Veristat, who worked day and night to submit our DSUR and our IND within thirty days of starting to work with us!
In addition to managing the process, the team worked seamlessly with us in the United States and our partner in Korea. Your team advised and guided us to produce quality submissions to meet our challenging corporate goal of submitting both on time. Due to these extraordinary efforts, we plan to work with you on our second IND submission.
Clinical Stage Biotechnology Company
Endocrine & Metabolic Highlights
|Dyslipidemia||Molybdenum cofactor deficiency (MoCD)|
|Gout||Nonalcoholic Steatohepatitis (NASH)|
|Growth Hormone Deficiencies/Abnormalities||Obesity|
|Homozygous Familial Hypercholesterolaemia||Osteoporosis|
|Hypercholesterolemia||Polycystic Ovary Syndrome (PCOS)|
|Hyperoxaluria||Vasomotor Symptoms (VMS)|
|Adrenoleukodystrophy (ALD)||Lipoprotein Lipase (LPL) Deficiency|
|Alagille Syndrome ALGS (liver disease)||Lysosomal Acid Lipase (LAL) Deficiency|
|Alpha-mannosidosis (AM)||Maroteaux-Lamy Syndrome|
|Bardet-Biedl Syndrome (BBS)||McArdle Disease|
|Cerebral Adrenoleukodystrophy (CALD)||Metachromatic Leukodystrophy (MLD)|
|Cerebrotendinous Xanthomatosis (CTX)||Methylmalonic Acidemia|
|Congenital Adrenal Hyperplasia (CAH)||Molybdenum Cofactor Deficiency (MoCD)|
|Duchenne Muscular Dystrophy (DMD)||Mucopolysaccharidosis IIIB & VI|
|Ehlers-Danlos Syndrome (EDS)||Mutase-Deficient Methylmalonic Acidemia (MMA)|
|Fabry Disease||Myotonic Dystrophy|
|Familial Amyloid Polyneuropathy||Neuroendocrine Tumors (NET)|
|Familial Chylomicronemia Syndrome (FCS)||Pediatric Congenital Athymia|
|Fatty Acid Oxidation Disorder (FAOD)||Phenylketonuria (PKU)|
|Fibrodysplasia Ossificans Progressvia (FOP)||Pompe Disease|
|Galactosemia||Primary Mitochondrial Myopathy (PMM)|
|Gaucher Disease||Progressive Familial Intrahepatic Cholestasis (PFIC)|
|Hereditary Transthyretin (hATTR) Amyloidosis||Pyruvate Kinase Deficiency|
|Homocystinuria||Recessive Dystrophic Epidermolysis Bullosa (RDEB)|
|Homozygous Familial Hypercholesterolaemia (HoFH)||Sanfilippo Syndrome|
|Hypoleptinemic Dysmetabolic Disorder||Wilson's Disease|
|Limb-girdle Muscular Dystrophy (LGMD)||X-linked Myotubular Myopathy|